89bio, Inc. (ETNB) Minute Stock Prediction

About:

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

26

Address:

89bio, Inc. 142 Sansome Street 2nd Floor San Francisco CA 94104 United States

Website:

Homepage

Phone:

415-500-4614